Last updated: September 7, 2026
Ramucirumab, marketed by Eli Lilly as Cyramza, is an anti-VEGFR-2 monoclonal antibody used in gastric and gastroesophageal junction cancer, non-small-cell lung cancer, colorectal cancer, and hepatocellular carcinoma. The product generated roughly $1 billion annually for Lilly in recent years, supported by multiple oncology indications and combination regimens.
Cyramza’s commercial outlook is stable but mature. Growth depends on continued use in lung, colorectal, and liver cancer, while the principal medium-term risk is the loss of U.S. biologic exclusivity in April 2026. No ramucirumab biosimilar had received U.S. approval through 2024, and no major publicly disclosed U.S. biosimilar litigation or settlement had materially altered the launch outlook by that point.
What is ramucirumab and how does Cyramza work?
Ramucirumab is a fully human immunoglobulin G1 monoclonal antibody that binds vascular endothelial growth factor receptor 2, or VEGFR-2. The drug blocks VEGF ligand signaling and inhibits angiogenesis, the formation of new blood vessels that support tumor growth.
Cyramza is administered by intravenous infusion. Its commercial use is generally tied to combination chemotherapy or prior-treatment requirements, except in selected hepatocellular carcinoma settings.
| Attribute |
Ramucirumab |
| Brand name |
Cyramza |
| Active ingredient |
Ramucirumab |
| Sponsor |
Eli Lilly and Company |
| Drug class |
Anti-VEGFR-2 monoclonal antibody |
| FDA approval |
April 21, 2014 |
| Administration |
Intravenous infusion |
| Primary markets |
United States, Europe, Japan, China and other international markets |
| Main indications |
Gastric/GEJ cancer, NSCLC, colorectal cancer, HCC |
| Regulatory category |
Biologic license application |
| U.S. biologic exclusivity |
Generally runs through April 21, 2026 |
Which cancer indications drive ramucirumab sales?
Cyramza has four major FDA-approved disease settings.
Gastric and gastroesophageal junction cancer
The FDA approved Cyramza in April 2014 as monotherapy for advanced or metastatic gastric or gastroesophageal junction adenocarcinoma after prior fluoropyrimidine- or platinum-containing chemotherapy. The agency later approved Cyramza with paclitaxel for patients whose disease progressed after prior chemotherapy.
The gastric-cancer indication established Cyramza as a commercial product but has faced intense competition from HER2-directed therapy, immune checkpoint inhibitors, chemotherapy combinations, and later-line treatment alternatives.
Non-small-cell lung cancer
Cyramza received FDA approval with docetaxel for metastatic NSCLC with disease progression during or after platinum-based chemotherapy. The indication covers both nonsquamous and squamous histologies, subject to treatment context.
Lung cancer is strategically important because of its large patient population. The market is competitive, with treatment selection increasingly driven by molecular biomarkers, PD-L1 status, immunotherapy combinations, antibody-drug conjugates, and targeted therapies.
Colorectal cancer
The FDA approved Cyramza with FOLFIRI for metastatic colorectal cancer that progressed during or after treatment with bevacizumab, oxaliplatin, and a fluoropyrimidine.
This indication places ramucirumab directly in a treatment sequence that already includes multiple antiangiogenic and targeted therapies. Its clinical and commercial differentiation depends on use after prior bevacizumab exposure and the physician’s preference among later-line options.
Hepatocellular carcinoma
In May 2019, the FDA approved Cyramza as a single agent for patients with hepatocellular carcinoma and alpha-fetoprotein levels of at least 400 ng/mL who previously received sorafenib.
The biomarker restriction creates a narrower addressable population than the lung or colorectal indications. It also gives Cyramza a defined position in the treatment pathway rather than broad first-line use.
How much revenue does Cyramza generate for Eli Lilly?
Cyramza became a billion-dollar oncology product after several years of indication expansion. Lilly’s annual reports show a progression from an early launch product to a mature global franchise.
| Fiscal year |
Approximate Cyramza revenue |
| 2014 |
$135 million |
| 2015 |
$330 million |
| 2016 |
$630 million |
| 2017 |
$760 million |
| 2018 |
$800 million |
| 2019 |
$950 million |
| 2020 |
About $1.0 billion |
| 2021 |
About $1.1 billion |
| 2022 |
About $1.0 billion |
| 2023 |
About $1.1 billion |
Figures are rounded from Eli Lilly annual reports and company financial disclosures. Lilly reports product sales by geographic market and currency-adjusted trends can differ from reported-dollar growth.
The financial trajectory has three phases:
- The 2014-2016 period reflected initial launch and rapid indication expansion.
- The 2017-2020 period reflected broader adoption in lung and colorectal cancer.
- The post-2020 period reflected mature demand, pricing pressure, foreign-exchange volatility, and competition from newer oncology medicines.
Cyramza is strategically meaningful but no longer central to Lilly’s corporate growth profile. The company’s recent valuation and revenue expansion have been driven more heavily by diabetes and obesity products, including Mounjaro and Zepbound, while Cyramza provides recurring oncology cash flow.
When does ramucirumab lose exclusivity?
Cyramza’s U.S. biologic exclusivity is expected to expire on April 21, 2026, 12 years after FDA approval of the original biologic license application. This date derives from the Biologics Price Competition and Innovation Act, which generally provides 12 years of reference-product exclusivity for biologics approved under the Public Health Service Act.
Loss of regulatory exclusivity does not automatically produce immediate biosimilar competition. A biosimilar sponsor must complete development, file an application, obtain FDA approval, complete the statutory patent notice process, and resolve or manage any patent litigation or settlement restrictions.
The commercial timing can therefore differ from the formal exclusivity date.
| Event |
Date or status |
| Original FDA approval |
April 21, 2014 |
| Expected end of 12-year biologic exclusivity |
April 21, 2026 |
| First possible routine U.S. biosimilar filing pathway |
Dependent on sponsor development and applicable patent strategy |
| First potential U.S. commercial entry |
Not established publicly through 2024 |
| Small-molecule generic pathway |
Not applicable |
What patents protect ramucirumab?
Ramucirumab is protected by a combination of biologic exclusivity, antibody-related patent claims, formulation and manufacturing know-how, and indication-specific intellectual property.
The most important distinction is between the reference product’s regulatory exclusivity and its patent estate. The 12-year biologic exclusivity period blocks approval of a biosimilar reference-product application for the statutory period, while patents can restrict development, approval, or commercial launch beyond that period.
Publicly available FDA sources identify Cyramza as a biologic rather than a conventional small-molecule product. Its protection is therefore less dependent on the typical Hatch-Waxman Orange Book litigation model used for tablets and capsules.
Orange Book status
Cyramza is not analyzed like a conventional oral drug with a conventional Orange Book patent-and-exclusivity profile. Biologic products licensed under the Public Health Service Act are generally evaluated through the FDA Purple Book and the BPCIA framework.
That means:
- A standard Orange Book Paragraph IV certification is not the primary U.S. biosimilar pathway.
- Biosimilar applicants rely on the abbreviated approval framework under section 351(k) of the Public Health Service Act.
- Patent disputes are managed through the BPCIA’s information-exchange and litigation procedures, often called the patent dance, although participation and timing can vary.
- State substitution rules for biosimilars differ from those for generic drugs.
Formulation and manufacturing protection
Cyramza’s commercial protection also includes proprietary cell-line development, antibody production, purification, analytical characterization, stability controls, and fill-finish processes. These barriers are difficult to reproduce even when the target and antibody sequence are publicly known.
A biosimilar applicant must demonstrate high similarity using analytical, pharmacokinetic, immunogenicity, and clinical evidence. Manufacturing comparability is a major cost and execution barrier. The product is an intravenous monoclonal antibody, so supply-chain and quality requirements are more demanding than for a conventional generic tablet.
Are there Paragraph IV challenges to Cyramza?
No conventional Paragraph IV generic challenge is expected because ramucirumab is a biologic, not a small-molecule drug approved under the Food, Drug, and Cosmetic Act’s abbreviated new drug application pathway.
The relevant competitive event is a 351(k) biosimilar application. Through 2024, no publicly disclosed FDA-approved ramucirumab biosimilar had established a U.S. launch date. The absence of an approved biosimilar reduced near-term erosion risk but did not eliminate post-2026 exposure.
The practical risks are:
- A biosimilar sponsor could file before April 2026 while planning approval or launch after exclusivity ends.
- Patent litigation could delay or accelerate entry depending on the asserted claims and settlement terms.
- Multiple biosimilar entrants could produce greater price erosion than a single entrant.
- Interchangeability status could affect hospital and payer substitution patterns.
Which companies are challenging ramucirumab?
No company had publicly established a commercial U.S. ramucirumab biosimilar challenge through 2024. The competitive pressure came primarily from alternative oncology treatments rather than direct biosimilar substitution.
Relevant competitive products and mechanisms include:
| Disease area |
Competitive pressure |
| Gastric/GEJ cancer |
Pembrolizumab-based therapy, trastuzumab for HER2-positive disease, chemotherapy, antibody-drug conjugates |
| NSCLC |
PD-1 and PD-L1 inhibitors, EGFR and ALK therapies, docetaxel combinations, antibody-drug conjugates |
| Colorectal cancer |
Bevacizumab, aflibercept, trifluridine/tipiracil, regorafenib, targeted therapy |
| HCC |
Atezolizumab plus bevacizumab, durvalumab combinations, tyrosine kinase inhibitors, later-line agents |
This competitive environment limits the ability to expand Cyramza through price increases or broad treatment-line migration.
What patent litigation affects Cyramza?
No major publicly reported U.S. patent litigation involving a ramucirumab biosimilar had materially changed the Cyramza market through 2024.
The litigation risk remains concentrated after the end of reference-product exclusivity. Potential disputes could involve:
- Antibody sequence and binding claims
- Methods of treating specific cancers
- Combination-treatment regimens
- Dosing schedules
- Formulation and stability claims
- Manufacturing and purification methods
Method-of-use patents can be commercially relevant even when they do not prevent a biosimilar from obtaining approval for every reference-product indication. A biosimilar sponsor may seek a label that excludes patented indications through a skinny-label strategy, although the practical risk of induced infringement depends on promotional conduct, prescribing patterns, and the scope of asserted claims.
How strong is the ramucirumab patent estate?
Cyramza has a moderately strong commercial protection profile through April 2026 because biologic exclusivity limits the regulatory pathway and the product requires complex manufacturing. Its post-2026 patent strength is harder to assess from public regulatory data alone because the decisive claims may involve formulation, manufacturing, dosing, or methods of use rather than a single composition-of-matter patent.
The estate is stronger in the near term than the medium term for four reasons:
- The 12-year biologic exclusivity period remains the most reliable barrier.
- IV monoclonal-antibody manufacturing creates a high technical entry hurdle.
- Multiple cancer indications create potential method-of-use rights.
- Cyramza’s established hospital and oncology-center supply chain raises operational requirements for entrants.
The estate is weaker against long-term competition because the target and clinical profile are mature, physicians have many alternative antiangiogenic therapies, and biosimilar developers can use the established clinical record to reduce development risk.
What licensing or acquisition deal created ramucirumab’s commercial position?
Lilly obtained ramucirumab through its 2008 acquisition of ImClone Systems for approximately $6.5 billion. ImClone had developed ramucirumab, then known as IMC-1121B, as an anti-VEGFR-2 antibody.
The transaction gave Lilly control of the antibody, development program, regulatory rights, and associated oncology capabilities. Public disclosures do not identify a major later external licensing transaction that has altered Cyramza’s global commercial structure.
What is the FDA regulatory status of Cyramza?
Cyramza is FDA-approved for four oncology indications:
| Indication |
Key FDA approval context |
| Gastric or GEJ adenocarcinoma |
Monotherapy after prior fluoropyrimidine- or platinum-containing chemotherapy |
| Gastric or GEJ adenocarcinoma |
Combination with paclitaxel after prior chemotherapy |
| Metastatic NSCLC |
Combination with docetaxel after platinum-based chemotherapy |
| Metastatic colorectal cancer |
Combination with FOLFIRI after bevacizumab, oxaliplatin and fluoropyrimidine |
| HCC |
Monotherapy after sorafenib in patients with AFP at least 400 ng/mL |
The product does not have the broad first-line positioning of some immune checkpoint inhibitors. Its value depends on defined treatment sequences and combination use.
What generic or biosimilar launch scenarios exist for ramucirumab?
Three launch scenarios are commercially relevant.
Delayed biosimilar entry
A biosimilar may receive approval after April 2026 but launch later because of patent litigation, settlement terms, manufacturing readiness, or market-access negotiations. This would preserve a substantial portion of Cyramza revenue during the first years after exclusivity.
Single-entrant entry
One biosimilar entrant could produce moderate price erosion, particularly in hospital channels and payer-controlled accounts. Lilly could defend share through contracting, service, supply reliability, and indication-specific positioning.
Multiple-entrant entry
Several biosimilars could produce sharper net-price declines. The impact would depend on interchangeability designations, oncology clinic purchasing, payer formularies, and the extent to which physicians view the products as substitutable.
A rapid collapse in revenue is less likely than with a small-molecule generic because biosimilar adoption is slower, manufacturing is complex, and treatment decisions are physician-directed. Revenue erosion could still become material once multiple suppliers compete.
How does ramucirumab compare with competing antiangiogenic drugs?
Ramucirumab’s main differentiator is direct VEGFR-2 blockade. Bevacizumab targets VEGF-A, while aflibercept acts as a soluble decoy receptor. The products overlap in colorectal, lung, and liver cancer treatment but occupy different lines and combinations.
| Product |
Primary target |
Main commercial advantage |
Key risk |
| Cyramza |
VEGFR-2 |
Multiple approved tumor types and later-line combinations |
Mature product and future biosimilar exposure |
| Avastin and biosimilars |
VEGF-A |
Broad oncology use and extensive biosimilar competition |
Price erosion |
| Zaltrap |
VEGF ligands |
Colorectal-cancer positioning |
Narrower commercial footprint |
| Immunotherapy products |
PD-1/PD-L1 |
First-line use in several tumors |
Biomarker and resistance limitations |
Cyramza is commercially more defensible than a single-indication oncology product, but it lacks the market expansion profile of a first-line immunotherapy or biomarker-defined targeted therapy with a large untreated population.
What is the revenue exposure to exclusivity loss?
Using annual sales near $1 billion, a 20% decline would reduce annual revenue by approximately $200 million, while a 40% decline would reduce revenue by approximately $400 million. A larger decline could occur if multiple biosimilars launch close together and payer substitution accelerates.
The exposure is manageable for Lilly at the corporate level because Cyramza represents a small share of total company revenue. It remains significant for oncology revenue planning, manufacturing utilization, and Lilly’s biologics portfolio.
Key Takeaways
- Ramucirumab is a mature, multi-indication oncology biologic marketed as Cyramza.
- Annual sales reached roughly $1 billion and remained near that level in the early 2020s.
- The main commercial markets are NSCLC, gastric and GEJ cancer, colorectal cancer, and biomarker-selected HCC.
- U.S. biologic exclusivity is expected to end on April 21, 2026.
- Paragraph IV generic litigation is not the relevant pathway; 351(k) biosimilar applications and BPCIA patent litigation are the key risks.
- No approved U.S. ramucirumab biosimilar or major public biosimilar settlement had established a launch date through 2024.
- Manufacturing complexity and physician-directed oncology use should slow erosion compared with conventional generic drugs.
- Cyramza’s principal competitive threat before biosimilar entry is treatment substitution by immunotherapies, targeted therapies, and other antiangiogenic agents.
- Lilly obtained the asset through its 2008 acquisition of ImClone Systems.
- The likely commercial outcome is gradual erosion after 2026, with faster decline if multiple biosimilar entrants launch in close succession.
FAQs about ramucirumab market exclusivity and competition
Is ramucirumab a chemotherapy drug?
No. Ramucirumab is a targeted monoclonal antibody that inhibits VEGFR-2. It is often administered with chemotherapy, but it is not a cytotoxic chemotherapy agent.
Does ramucirumab have a biosimilar?
No FDA-approved ramucirumab biosimilar had been established through 2024. The first U.S. biosimilar launch date remains dependent on development, FDA review, patent resolution, and commercial strategy.
Can a ramucirumab biosimilar receive interchangeability?
Potentially. A sponsor would need to pursue the FDA’s interchangeability standard under the 351(k) pathway. Interchangeability is separate from biosimilarity and can affect pharmacy and payer substitution.
What company originally developed ramucirumab?
ImClone Systems developed ramucirumab before Eli Lilly acquired ImClone in 2008 for approximately $6.5 billion.
Will Cyramza sales end immediately when exclusivity expires?
No. Sales generally decline over time rather than ending on the exclusivity date. The pace depends on biosimilar approvals, patent disputes, launch timing, pricing, contracting, interchangeability, and physician adoption.
References
-
Eli Lilly and Company. (2008). Eli Lilly and Company to acquire ImClone Systems Incorporated. Eli Lilly investor relations.
-
Eli Lilly and Company. (2015-2024). Annual reports and Form 10-K filings. Eli Lilly and Company.
-
U.S. Food and Drug Administration. (2014, April 21). FDA approves Cyramza for advanced stomach cancer. FDA.
-
U.S. Food and Drug Administration. (2014-2019). Cyramza prescribing information. FDA.
-
U.S. Food and Drug Administration. (2019, May 10). FDA approves Cyramza for hepatocellular carcinoma. FDA.
-
U.S. Food and Drug Administration. (2024). Purple Book: Lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations. FDA.
-
U.S. Congress. (2010). Patient Protection and Affordable Care Act, Title VII: Improving access to innovative medical therapies. 42 U.S.C. § 262.
